Core Insights - Adaptive Biotechnologies Corporation is showcasing the increasing interventional use of its clonoSEQ® test at the 67th American Society of Hematology Annual Meeting, with 90 abstracts featuring clonoSEQ data [1] - The clonoSEQ test is being utilized to guide clinical decisions in blood cancer treatment, particularly in assessing measurable residual disease (MRD) status [3][8] Group 1: Clinical Studies and Findings - The phase II EndRAD study supports the use of next-generation sequencing (NGS) MRD status prior to allogeneic hematopoietic cell transplantation (HCT) to select non-total body irradiation (TBI) conditioning approaches, showing excellent event-free and overall survival in 51 NGS MRD negative patients [2] - In multiple myeloma (MM), a phase III AURIGA study demonstrated that deep MRD responses correlate with improved progression-free survival, with intensified maintenance post-transplant doubling MRD negativity rates [7] - A phase II study in chronic lymphocytic leukemia (CLL) showed that a combination therapy achieved deep and durable remissions based on MRD assessment, highlighting clonoSEQ's role in guiding treatment duration [7] Group 2: Impact on Treatment Approaches - clonoSEQ MRD status is being used by healthcare providers to tailor treatment intensity and duration, enhancing precision in clinical decision-making [3][8] - The data presented at ASH indicates a shift towards using clonoSEQ to de-escalate therapy in certain patient populations, such as frail older adults with diffuse large B-cell lymphoma (DLBCL) [7] - The unprecedented volume of data at ASH reinforces clonoSEQ's leadership in blood cancer MRD monitoring, reflecting its value in therapeutic progress and patient management [8] Group 3: Product Overview - clonoSEQ is the first FDA-cleared in vitro diagnostic test for detecting and tracking MRD in patients with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia [9] - The test identifies and quantifies DNA sequences in malignant cells, detecting one cancer cell in one million healthy cells, which aids clinicians in monitoring MRD with precision [10] - clonoSEQ is covered by Medicare for multiple myeloma, CLL, ALL, DLBCL, and mantle cell lymphoma, indicating its established role in clinical practice [9]

Core Insights - Adaptive Biotechnologies Corporation is showcasing the increasing interventional use of its clonoSEQ test at the 67th American Society of Hematology Annual Meeting, with 90 abstracts featuring clonoSEQ data, including 17 that demonstrate its role in guiding clinical actions for blood cancer patient care [1][9] Group 1: Clinical Applications and Studies - The phase II EndRAD study supports the use of next-generation sequencing (NGS) measurable residual disease (MRD) status prior to allogeneic hematopoietic cell transplantation (HCT) to select non-total body irradiation (TBI) conditioning approaches, showing excellent event-free and overall survival in 51 NGS MRD negative patients [2][3] - Across hematologic malignancies, clonoSEQ MRD status is utilized by healthcare providers to guide clinical decisions, with presentations demonstrating its application in tailoring treatment intensity and duration [3][9] - A phase III AURIGA study involving 200 newly diagnosed multiple myeloma (MM) patients showed that deep MRD responses correlated with improved progression-free survival, and intensified maintenance in MRD-positive patients post-transplant doubled MRD negativity rates [7] Group 2: Abstracts and Research Findings - A total of 32 abstracts on multiple myeloma will be presented, focusing on MRD assessment of treatment response and real-world data linking MRD status to clinical outcomes [7] - In non-Hodgkin lymphoma (NHL), 15 abstracts will explore MRD to understand treatment response depth and guide therapy, including a study on de-escalating therapy in frail older adults with diffuse large B-cell lymphoma (DLBCL) [7] - Data from a phase II study of 80 previously untreated chronic lymphocytic leukemia (CLL) patients indicated that time-limited therapy achieved deep and durable remissions based on MRD assessment [8] Group 3: clonoSEQ Overview - clonoSEQ is the first FDA-cleared in vitro diagnostic test for detecting and tracking MRD in patients with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, and is also available for other lymphoid cancers as a CLIA-validated laboratory developed test [10][11] - The test identifies and quantifies DNA sequences in malignant cells, detecting one cancer cell in one million healthy cells, providing standardized and sensitive results that inform treatment decisions and predict outcomes [11]

Disease Diagnosis and Treatment - Hematopathology specializes in diagnosing diseases associated with blood, bone marrow, lymph nodes, and clotting mechanisms, utilizing advanced techniques like flow cytometry and molecular diagnostics [1] - Flow cytometry is used to convert cells into dots on a plot, aiding in the diagnosis and monitoring of blood cancers [3] - Measurable Residual Disease (MRD) detection via flow cytometry helps assess therapy effectiveness [4] - CAR T-cell therapy, where a patient's own immune cells are trained to fight cancer cells, shows promise in treating relapsed blood cancers [4] Technological Advancements - Flow cytometers use optics, fluidics, and electronics to analyze cells, detecting fluorescently labeled antibodies bound to antigens [3] - The integration of clinical knowledge, immunology, flow cytometry, and molecular biology is crucial for modern hematology [4] Impact and Training - Tata Memorial Center sees approximately 4,000 new blood cancer patients annually [4] - The center provides training to dozens of trainees, technicians, and pathologists from across the country and neighboring countries, focusing on understanding the science behind the data [4] - The ultimate goal is to provide patients with second chances, hope, and the opportunity to live out their dreams [4][5]

Core Viewpoint - The integration of Adaptive Biotechnologies' clonoSEQ test for measurable residual disease (MRD) assessment into Flatiron Health's OncoEMR platform enhances access to MRD testing for clinicians, improving treatment decision-making for blood cancer patients [1][2][3][4]. Company Overview - Adaptive Biotechnologies is a commercial-stage biotechnology company focused on translating the genetics of the adaptive immune system into clinical products for disease diagnosis and treatment [8][9]. - Flatiron Health is a healthtech company dedicated to advancing point-of-care solutions in oncology, utilizing data to improve cancer care [10]. Product Integration - The clonoSEQ test will be integrated into OncoEMR, allowing over 4,500 clinicians across 1,000 community-based cancer care locations in the U.S. to order and review MRD testing results directly within the EMR [2][4]. - This integration aims to streamline access to MRD data, enabling community clinicians to make more informed treatment decisions for blood cancer patients [3][4]. Clinical Significance - clonoSEQ is the first FDA-cleared in vitro diagnostic test for detecting and tracking MRD in multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, among other lymphoid cancers [5][6]. - The test can detect one cancer cell in one million healthy cells, providing precise monitoring of MRD over time, which is crucial for predicting patient outcomes and informing treatment strategies [6][7]. Market Impact - The integration of clonoSEQ into OncoEMR is expected to enhance the efficiency of testing workflows and provide real-time insights into patients' disease status, ultimately improving patient care in community oncology settings [2][4][11].